Skip to main content
. 2020 Jul 13;4(13):3141–3153. doi: 10.1182/bloodadvances.2020001852

Figure 4.

Figure 4.

OS and PFS stratified by treatment options in early-stage patients receiving non–ANT-based or ANT-based regimens. OS (A) and PFS (B) of CMT vs CT alone in early-stage patients receiving non–ANT-based regimens before PSM. OS (C) and PFS (D) of CMT vs CT alone in early-stage patients receiving ANT-based regimens before PSM.